HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

Autor: Laura Sighinolfi, Guido Palamara, Massimo Di Pietro, Barbara Ensoli, Angela Arancio, Sonia Moretti, Mauro Magnani, Stefania Bellino, Fabrizio Ensoli, Vito S. Mercurio, Francesco Castelli, Leonardo Sernicola, Enrico Garaci, Maria Teresa Maggiorella, Andrea Gori, Giovanni Di Perri, Cecilia Sgadari, Massimo Galli, Vittorio Francavilla, Orietta Picconi, Anna Casabianca, Olimpia Longo, Chiara Orlandi, Aurelio Cafaro, Adriano Lazzarin, Antonella Tripiciano, Cristina Mussini, Maria Rosaria Pavone Cossut, Giovanni Paniccia, Gioacchino Angarano, Paolo Monini
Přispěvatelé: Ensoli, F, Cafaro, A, Casabianca, A, Tripiciano, A, Bellino, S, Longo, O, Francavilla, V, Picconi, O, Sgadari, C, Moretti, S, Cossut, M, Arancio, A, Orlandi, C, Sernicola, L, Maggiorella, M, Paniccia, G, Mussini, C, Lazzarin, A, Sighinolfi, L, Palamara, G, Gori, A, Angarano, G, Di Pietro, M, Galli, M, Mercurio, V, Castelli, F, Di Perri, G, Monini, P, Magnani, M, Garaci, E, Ensoli, B
Rok vydání: 2015
Předmět:
Male
HAART
Antibodie
HIV Antibodies
CD38
Antibodies
CD38+HLA-DR+/CD8+ T cells
HIV-1
Neutralization
Proviral DNA
Tat protein
Vaccine
AIDS Vaccines
Acquired Immunodeficiency Syndrome
Adult
Antibodies
Neutralizing
Antiretroviral Therapy
Highly Active
CD4 Lymphocyte Count
Female
Follow-Up Studies
Humans
Immunoglobulin G
Immunoglobulin M
Italy
Leukocytes
Middle Aged
Treatment Outcome
Young Adult
tat Gene Products
Human Immunodeficiency Virus
Viral Load
Virology
Infectious Diseases
Medicine
+
HLA-DR
CD8
T cells
Neutralizing
biology
Immunogenicity
Vaccination
CD38+HLA-DR+/CD8+ T cell
Antibody
tat Gene Products
Viral load
Human Immunodeficiency Virus
Antiretroviral Therapy
Viremia
Immune system
Highly Active
business.industry
Research
medicine.disease
Immunization
Immunology
biology.protein
business
Zdroj: Retrovirology
ISSN: 1742-4690
Popis: Background The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at exploring immunological and virological disease biomarkers. The study duration was 48 weeks, however, vaccinees were followed until the last enrolled subject reached the 48 weeks. Reported are final data up to 144 weeks of follow-up. The ISS T-002 trial was conducted in 11 clinical centers in Italy on 168 HIV positive subjects under Highly Active Antiretroviral Therapy (HAART), anti-Tat Antibody (Ab) negative at baseline, with plasma viremia
Databáze: OpenAIRE
Externí odkaz: